What is it about?
Overview of data on the following compounds: aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, cefiderocol, ceftaroline/avibactam, ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, meropenem/nacubactam and meropenem/vaborbactam
Featured Image
Photo by CDC on Unsplash
Why is it important?
Provides a pragmatic overview on the new BL/BLIs and cefiderocol
Read the Original
This page is a summary of: Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians, December 2023, Authorea, Inc.,
DOI: 10.22541/au.170259036.66886277/v1.
You can read the full text:
Contributors
The following have contributed to this page
